upadacitinib   Click here for help

GtoPdb Ligand ID: 9246

Synonyms: ABT-494 | Rinvoq®
Approved drug Immunopharmacology Ligand
upadacitinib is an approved drug (EMA & FDA (2019))
Compound class: Synthetic organic
Comment: Upadacitinib (ABT-494) is a novel second generation orally active Janus kinase inhibitor with high JAK1 selectivity [5,10]. The chemical structure is claimed as compound 1 in Abbvie's patent WO2015061665 [10]. It was developed for potential clinical efficacy in multiple autoimmune diseases. Its first approval was for the treatment of rheumatoid arthritis [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 78.32
Molecular weight 380.16
XLogP 3.06
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCC1CN(CC1c1cnc2n1c1cc[nH]c1nc2)C(=O)NCC(F)(F)F
Isomeric SMILES CC[C@@H]1CN(C[C@@H]1c1cnc2n1c1cc[nH]c1nc2)C(=O)NCC(F)(F)F
InChI InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1
InChI Key WYQFJHHDOKWSHR-MNOVXSKESA-N
Classification Click here for help
Compound class Synthetic organic
Approved drug? Yes (EMA & FDA (2019))
International Nonproprietary Names Click here for help
INN number INN
10209 upadacitinib
Synonyms Click here for help
ABT-494 | Rinvoq®
Database Links Click here for help
DrugCentral Ligand 5346
GtoPdb PubChem SID 315661321
PubChem CID 58557659
Search Google for chemical match using the InChIKey WYQFJHHDOKWSHR-MNOVXSKESA-N
Search Google for chemicals with the same backbone WYQFJHHDOKWSHR
Search PubMed clinical trials upadacitinib
Search PubMed titles upadacitinib
Search PubMed titles/abstracts upadacitinib
UniChem Compound Search for chemical match using the InChIKey WYQFJHHDOKWSHR-MNOVXSKESA-N
UniChem Connectivity Search for chemical match using the InChIKey WYQFJHHDOKWSHR-MNOVXSKESA-N